The Food and Drug Administration has given its approval of BELKIN Vision's new glaucoma laser device, known as the Eagle.
With more than 3.6 million patients in the United States living with a diagnosis of glaucoma, this new laser offers the first and only contactless laser for glaucoma. It gives patients and their doctors an automated and non-invasive treatment option. Laser trabeculoplasty can be used as either an initial or adjunctive therapy in patients with primary open angle glaucoma.
The Eagle device offers a few advantages over traditional treatment options. The use of a gonioscopy lens is not necessary because the laser energy is delivered via a non-contact procedure directly through the lumbus to the trabecular meshwork. In addition, the Eagle automatically defines the target location and then administers the laser treatment sequence while the eye tracker makes up for any eye movement.
